الفهرس 
Patients and mithodsOnly 14 pages are availabe for public view
 |  | from | 165 |  |  |
| | | from | 165 | | |
Abstract
The purpose of this study is to evaluate the role of IGFBP-3 in inflammatory and degenerative joint diseases by estimating its level in the serum and synovial fluid of patients with RA and OA and correlating these levels to the clinical and radiological features of these disorders.
Twenty RA patients, twenty eight OA patients and fourteen controls were included in this study. Cases were selected consecutively from the outpatient clinic and in-patient ward of the rheumatology and rehabilitation department, Benha faculty of medicine.
Patients and controls were subjected to the following :
I.Full history and clinical examination
II.Laboratory investigations including CBC, ESR, RF for RA patients
III.Estimation of the level of IGFBP-3 in both serum and synovial fluid by radioactive immuno assay procedure for all patients.
IV.Plain x-ray for both knees & hands for all patients.
Patients with RA were divided according to their radiological findings into erosive and non erosive sub groups, and according to
the MDAG into two groups, one including patients with MDAG 1, & 2 and another including patients with MDAG3 & 4.
We divided OA patients according to radiological findings into two sub groups, one including patients with grade 1 & II x-ray findings and another including grade III & IV patients. According to score of functional severity, we subgrouped our OA patients into two
subgroups; one including patients with score < 7 and another including patients with score > 8.
Our results showed that :
1)For controls, the mean serum IGFBP-3 level was 2828.6 ± 709.7 ng/ml and mean synovial levels was 425 + 195.2 ng/ml.
2)For RA patients, the mean serum IGFBP-3 level was 3220 ± 1485.9 ng/ml and mean synovial levels was 601 ± 171.9 ng/ml.
3)For OA patients, the mean serum IGFBP-3 level was 3250 + 744.1 ng/ml and mean synovial level was 500 + 113.3 ng/ml.
4)We found no significant difference (P > 0.05) between the serum level of the IGFBP-3 of both RA and OA patients when compared to the controls.
5)A significant increase (P < 0.05) was found in the synovial IGFBP-3 of RA patients when compared to the controls.
6)No significant difference (P > 0.05) was found between synovial IGFBP-3 of OA patients when compared to the
controls.
7)The serum and synovial levels of IGFBP-3 of RA patients were not found to correlate significantly (P > 0.05) with the radiological findings or the mean disease activity grade.
8)The serum and synovial level of IGFBP-3 of OA patients were not found to correlate significantly (P > 0.05) with the radiological findings or the score of functional severity.
No significant correlation (P > 0.05) was found between the serum and synovial IGFBP-3 of the RA patients or OA patients with sex, age and disease duration.
No significant difference (P > 0.05) was found between IGFBP-3 level in serum and synovial fluid of seropositive RA patients when compared to seronegative RA patients.
0.05) was found between serum IGFBP-3 of RA patients and the hemoglobin concentration.